{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:40:42Z","timestamp":1777934442894,"version":"3.51.4"},"reference-count":8,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) is more toxic than gemcitabine, but it is a safe regimen with manageable toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>We report a case with steatohepatitis mimicking liver metastasis as toxicity that was not seen in study patient population. Management and outcome: In the adjuvant statement with FOLFIRINOX due to biopsy, we give the same regimen by excluding metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The adverse events of drugs are important predictive factor for treatment management, as important as efficacy. Especially the new lesion and metastasis is the most important factor for changing treatment. The clinicians must be careful about adverse events of regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>FOLFIRINOX regimen is the most important combination in pancreas cancer adjuvant setting. This case shows us the different presentation of usual adverse event.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220904422","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:40:59Z","timestamp":1582072859000},"page":"1738-1742","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Steatohepatitis due to FOLFIRINOX regimen in adjuvant pancreas cancer treatment mimicking liver metastasis"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0295-6295","authenticated-orcid":false,"given":"Berna","family":"Bozkurt Duman","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Adana City Education and Research Hospital, Adana, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timu\u00e7in","family":"\u00c7il","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Adana City Education and Research Hospital, Adana, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,2,18]]},"reference":[{"key":"bibr1-1078155220904422","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923"},{"key":"bibr2-1078155220904422","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809775"},{"key":"bibr3-1078155220904422","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2005.01.024"},{"key":"bibr4-1078155220904422","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4103\/jrms.JRMS_793_17","volume":"23","author":"Emami H","year":"2018","journal-title":"J Res Med Sci"},{"key":"bibr5-1078155220904422","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2015.08.022"},{"key":"bibr6-1078155220904422","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2012.08.030"},{"key":"bibr7-1078155220904422","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.3074"},{"key":"bibr8-1078155220904422","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e318187ef32"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220904422","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220904422","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220904422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:22:35Z","timestamp":1777688555000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220904422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,18]]},"references-count":8,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1177\/1078155220904422"],"URL":"https:\/\/doi.org\/10.1177\/1078155220904422","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,18]]}}}